Monoterapia ou terapia combinada com inibidores de checkpoint imunológico: comparando efeitos aditivos e mecanismos diferenciais na resposta antitumoral

Autores

  • Maria Fernanda Figueiredo de Souza Faculdade de Medicina de Petrópolis Autor
  • Gabriel Pessanha Amorim Faculdade de Medicina de Petrópolis Autor
  • Ana Carolina de Oliveira Rodrigues Faculdade de Medicina de Petrópolis Autor
  • Joanna Dale Coutinho Pereira Silva Faculdade de Medicina de Petrópolis Autor
  • Isabela Stumpf Marques Faculdade de Medicina de Petrópolis Autor
  • Aline Grandis Guimarães Faculdade de Medicina de Petrópolis Autor
  • Joana Gonzalez Ambrosio Izzo do Amaral Faculdade de Medicina de Petrópolis Autor
  • Patricia Quadrio de Oliveira Veiga Faculdade de Medicina de Petrópolis Autor
  • Gustavo Andrade Vitoi Faculdade de Medicina de Petrópolis Autor
  • Giovanna Avallone Faculdade de Medicina de Petrópolis Autor

DOI:

https://doi.org/10.5281/zenodo.13729930

Palavras-chave:

Inibidores de checkpoint, Anti-PD-1, Anti-CTLA-4, Terapia combinada, Sinergismo

Resumo

O câncer é um problema de saúde pública no Brasil e no mundo, com estimativas de 18 milhões de novos casos surgindo globalmente em 2018 e mais de 600 mil novos casos no Brasil em 2020. A mortalidade relacionada à doença é alarmante, com 9,6 milhões de óbitos por câncer em 2018. As células do sistema imune, principalmente os linfócitos T CD8, desempenham um papel fundamental na defesa contra tumores. No entanto, os mecanismos de evasão imunológica, como a diminuição da expressão de MHC de classe I nas células tumorais e a ação de checkpoints imunológicos como CTLA-4 e PD-1, dificultam a eficácia da resposta imune. O CTLA-4 inibe a ativação de linfócitos, enquanto o PD-1, ao interagir com seus ligantes, limita a função dos linfócitos, favorecendo a sobrevivência tumoral. A imunoterapia de bloqueio de checkpoint, com fármacos como Ipilimumabe (anti-CTLA-4) e Nivolumabe (anti-PD-1), tem mostrado resultados promissores, aumentando a sobrevida e a resposta em pacientes com câncer. A combinação dessas terapias apresenta melhores resultados do que as monoterapias, mostrando maior eficácia e capacidade de ativação de células T efetoras. No entanto, existem preocupações quanto aos efeitos adversos e à compreensão dos mecanismos moleculares envolvidos. A terapia combinada induz um perfil de expressão de genes e uma resposta imunológica distinta, sugerindo ações sinérgicas. Apesar dos resultados encorajadores, a necessidade de mais pesquisas para compreender plenamente essa sinergia e otimizar a terapia continua evidente, a fim de melhorar a aplicação clínica e os padrões de tratamento para o câncer.

Biografia do Autor

  • Maria Fernanda Figueiredo de Souza , Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Gabriel Pessanha Amorim , Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Joanna Dale Coutinho Pereira Silva, Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Isabela Stumpf Marques, Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Aline Grandis Guimarães, Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Joana Gonzalez Ambrosio Izzo do Amaral , Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Patricia Quadrio de Oliveira Veiga, Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Gustavo Andrade Vitoi, Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

  • Giovanna Avallone, Faculdade de Medicina de Petrópolis

    Estudante de graduação de Medicina na Faculdade de Medicina de Petrópolis

Referências

GAROFOLO, Adriana et al . Dieta e câncer: um enfoque epidemiológico. Rev. Nutr., Campinas , v. 17, n. 4, p. 491-505, Dez. 2004 . Disponível em: <http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-52732004000400009&lng=en&nrm=iso>. Acesso em 22 Ago. 2020. http://dx.doi.org/10.1590/S1415-52732004000400009.

BRAY, Freddie et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for cancers in 185 countries. CA Cancer J Clin, [S. l.], p. 394-424, Nov. 2018. DOI 10.3322/caac.21492. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30207593/. Acesso em: 16 ago. 2020.

BITTENCOURT, Rosane et al. Perfil epidemiológico do câncer na rede pública em Porto Alegre - RS. Revista Brasileira de Cancerologia, [S. l.], v. 50, n. 2, p. 95-101,2004.

MS / INCA / Estimativa de Câncer no Brasil, 2020

Stewart BW, Wild CP, editors. World cancer report 2014. Lyon: International Agency for Research on Cancer; 2014.

ZAMARIN, Dmitriy; BURGER, Robert A.; SILL, Michael W.; POWELL, Daniel J.; LANKES, Heather A.; FELDMAN, Michael D.; ZIVANOVIC, Oliver; GUNDERSON, Camille; KO, Emily; MATHEWS, Cara. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: an nrg oncology study. Journal Of Clinical Oncology, [S.L.], v. 38, n. 16, p. 1814-1823, 1 jun. 2020. American Society of Clinical Oncology (ASCO). http://dx.doi.org/10.1200/jco.19.02059.

KOOSHKAKI, Omid; DERAKHSHANI, Afshin; HOSSEINKHANI, Negar; TORABI, Mitra; SAFAEI, Sahar; BRUNETTI, Oronzo; RACANELLI, Vito; SILVESTRIS, Nicola; BARADARAN, Behzad. Combination of Ipilimumab and Nivolumab in Cancers: from clinical practice to ongoing clinical trials. International Journal Of Molecular Sciences, [S.L.], v. 21, n. 12, p. 4427, 22 jun. 2020. MDPI AG. http://dx.doi.org/10.3390/ijms21124427.

MARIN-ACEVEDO, Julian A.; DHOLARIA, Bhagirathbhai; SOYANO, Aixa E.; KNUTSON, Keith L.; CHUMSRI, Saranya; LOU, Yanyan. Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal Of Hematology & Oncology, [S.L.], v. 11, n. 1, 15 mar. 2018. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s13045-018-0582-8.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856308/

PARDOLL, Drew M.. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, [S.L.], v. 12, n. 4, p. 252-264, 22 mar. 2012. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nrc3239.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023/

ROWSHANRAVAN, Behzad; HALLIDAY, Neil; SANSOM, David M.. CTLA-4: a moving target in immunotherapy. Blood, [S.L.], v. 131, n. 1, p. 58-67, 4 jan. 2018. American Society of Hematology. http://dx.doi.org/10.1182/blood-2017-06-741033.

(Busca Geral: “CTLA-4”)

KRUGER, Stephan; ILMER, Matthias; KOBOLD, Sebastian; CADILHA, Bruno L.; ENDRES, Stefan; ORMANNS, Steffen; SCHUEBBE, Gesa; RENZ, Bernhard W.; D’HAESE, Jan G.; SCHLOESSER, Hans. Advances in cancer immunotherapy 2019 – latest trends. Journal Of Experimental & Clinical Cancer Research, [S.L.], v. 38, n. 1, p. 1-11, 19 jun. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s13046-019-1266-0.

ALTMANN, Daniel M.. A Nobel Prize‐worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens. Immunology, [S.L.], v. 155, n. 3, p. 283-284, 15 out. 2018. Wiley. http://dx.doi.org/10.1111/imm.13008.

BOUTROS, Celine; TARHINI, Ahmad; ROUTIER, Emilie; LAMBOTTE, Olivier; LADURIE, Francois Leroy; CARBONNEL, Franck; IZZEDDINE, Hassane; MARABELLE, Aurelien; CHAMPIAT, Stephane; BERDELOU, Armandine. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, [S.L.], v. 13, n. 8, p. 473-486, 4 maio 2016. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nrclinonc.2016.58.

APETOH, Lionel; GHIRINGHELLI, François; TESNIERE, Antoine; OBEID, Michel; ORTIZ, Carla; CRIOLLO, Alfredo; MIGNOT, Grégoire; MAIURI, M Chiara; ULLRICH, Evelyn; SAULNIER, Patrick. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, [S.L.], v. 13, n. 9, p. 1050-1059, 19 ago. 2007. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nm1622.

FARKONA, Sofia; DIAMANDIS, Eleftherios P.; BLASUTIG, Ivan M.. Cancer immunotherapy: the beginning of the end of cancer?. Bmc Medicine, [S.L.], v. 14, n. 1, p. 1-18, 5 maio 2016. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12916-016-0623-5.

KIMIZ-GEBOLOGLU, Ilgin; GULCE-IZ, Sultan; BIRAY-AVCI, Cigir. Monoclonal antibodies in cancer immunotherapy. Molecular Biology Reports, [S.L.], v. 45, n. 6, p. 2935-2940, 11 out. 2018. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s11033-018-4427-x.

MARIN-ACEVEDO, Julian A.; SOYANO, Aixa E.; DHOLARIA, Bhagirathbhai; KNUTSON, Keith L.; LOU, Yanyan. Cancer immunotherapy beyond immune checkpoint inhibitors. Journal Of Hematology & Oncology, [S.L.], v. 11, n. 1, p. 1-25, 12 jan. 2018. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s13045-017-0552-6.

YANG, Yiping. Cancer immunotherapy: harnessing the immune system to battle cancer. Journal Of Clinical Investigation, [S.L.], v. 125, n. 9, p. 3335-3337, 1 set. 2015. American Society for Clinical Investigation. http://dx.doi.org/10.1172/jci83871.

HAANEN, John B.A.G.; ROBERT, Caroline. Immune Checkpoint Inhibitors. Progress In Tumor Research, [S.L.], p. 55-66, 2015. S. Karger AG. http://dx.doi.org/10.1159/000437178.

SHARMA, Padmanee; SIEFKER-RADTKE, Arlene; BRAUD, Filippo de; BASSO, Umberto; CALVO, Emiliano; BONO, Petri; MORSE, Michael A.; ASCIERTO, Paolo A.; LOPEZ-MARTIN, Jose; BROSSART, Peter. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: checkmate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. Journal Of Clinical Oncology, [S.L.], v. 37, n. 19, p. 1608-1616, 1 jul. 2019. American Society of Clinical Oncology (ASCO). http://dx.doi.org/10.1200/jco.19.00538.

MELLMAN, Ira; COUKOS, George; DRANOFF, Glenn. Cancer immunotherapy comes of age. Nature, [S.L.], v. 480, n. 7378, p. 480-489, dez. 2011. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nature10673.

GAO, Xin; MCDERMOTT, David F.. Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. Expert Opinion On Biological Therapy, [S.L.], v. 18, n. 9, p. 947-957, 30 ago. 2018. Informa UK Limited. http://dx.doi.org/10.1080/14712598.2018.1513485.

HELLMANN, Matthew D.; CIULEANU, Tudor-Eliade; PLUZANSKI, Adam; LEE, Jong Seok; OTTERSON, Gregory A.; AUDIGIER-VALETTE, Clarisse; MINENZA, Elisa; LINARDOU, Helena; BURGERS, Sjaak; SALMAN, Pamela. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. New England Journal Of Medicine, [S.L.], v. 378, n. 22, p. 2093-2104, 31 maio 2018. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1801946.

MOTZER, Robert J.; TANNIR, Nizar M.; MCDERMOTT, David F.; FRONTERA, Osvaldo Arén; MELICHAR, Bohuslav; CHOUEIRI, Toni K.; PLIMACK, Elizabeth R.; BARTHÉLÉMY, Philippe; PORTA, Camillo; GEORGE, Saby. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal Of Medicine, [S.L.], v. 378, n. 14, p. 1277-1290, 5 abr. 2018. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1712126.

MOTZER, Robert J; RINI, Brian I; MCDERMOTT, David F; FRONTERA, Osvaldo Arén; HAMMERS, Hans J; A CARDUCCI, Michael; SALMAN, Pamela; ESCUDIER, Bernard; BEUSELINCK, Benoit; AMIN, Asim. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. The Lancet Oncology, [S.L.], v. 20, n. 10, p. 1370-1385, out. 2019. Elsevier BV. http://dx.doi.org/10.1016/s1470-2045(19)30413-9.

HELLMANN, Matthew D.; CALLAHAN, Margaret K.; AWAD, Mark M.; CALVO, Emiliano; ASCIERTO, Paolo A.; ATMACA, Akin; RIZVI, Naiyer A.; HIRSCH, Fred R.; SELVAGGI, Giovanni; SZUSTAKOWSKI, Joseph D.. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, [S.L.], v. 33, n. 5, p. 853-861.e4, maio 2018. Elsevier BV. http://dx.doi.org/10.1016/j.ccell.2018.04.001.

HAMMERS, Hans J.; PLIMACK, Elizabeth R.; INFANTE, Jeffrey R.; RINI, Brian I.; MCDERMOTT, David F.; LEWIS, Lionel D.; VOSS, Martin H.; SHARMA, Padmanee; PAL, Sumanta K.; RAZAK, Albiruni R. Abdul. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: the checkmate 016 study. Journal Of Clinical Oncology, [S.L.], v. 35, n. 34, p. 3851-3858, 1 dez. 2017. American Society of Clinical Oncology (ASCO). http://dx.doi.org/10.1200/jco.2016.72.1985.

HELLMANN, Matthew D.; PAZ-ARES, Luis; CARO, Reyes Bernabe; ZURAWSKI, Bogdan; KIM, Sang-We; COSTA, Enric Carcereny; PARK, Keunchil; ALEXANDRU, Aurelia; LUPINACCI, Lorena; JIMENEZ, Emmanuel de La Mora. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. New England Journal Of Medicine, [S.L.], v. 381, n. 21, p. 2020-2031, 21 nov. 2019. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1910231.

DANIEL VARGAS P. DE ALMEIDA (Brasil). Manual de Oncologia Clínica do Brasil. Novo regime de administração de imunoterapia recebe aprovação do FDA. 2018. Disponível em: https://mocbrasil.com/blog/uncategorized/novo-regime-de-administracao-de-imunoterapia-recebe-aprovacao-do-fda/#:~:text=No%20Brasil%2C%20o%20nivolumabe%20%C3%A9,bexiga%2C%20que%20recebeu%20aprova%C3%A7%C3%A3o%20recentemente. Acesso em: 18 ago. 2020.

Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2020. Disponível em: https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications. Acesso em: 18 ago. 2020.

LECLERC, Marine; VOILIN, Elodie; GROS, Gwendoline; CORGNAC, Stéphanie; MONTPRÉVILLE, Vincent de; VALIDIRE, Pierre; BISMUTH, Georges; MAMI-CHOUAIB, Fathia. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nature Communications, [S.L.], v. 10, n. 1, p. 1-14, 26 jul. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/s41467-019-11280-z.

LARKIN, James; CHIARION-SILENI, Vanna; GONZALEZ, Rene; GROB, Jean-Jacques; RUTKOWSKI, Piotr; LAO, Christopher D.; COWEY, C. Lance; SCHADENDORF, Dirk; WAGSTAFF, John; DUMMER, Reinhard. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal Of Medicine, [S.L.], v. 381, n. 16, p. 1535-1546, 17 out. 2019. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1910836.

YANG, Yi; JIN, Gang; PANG, Yao; HUANG, Yijie; WANG, Wenhao; ZHANG, Hongyi; TUO, Guangxin; WU, Peng; WANG, Zequan; ZHU, Zijiang. Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: a systematic review and meta-analysis. Frontiers In Pharmacology, [S.L.], v. 11, p. 1-10, 14 fev. 2020. Frontiers Media SA. http://dx.doi.org/10.3389/fphar.2020.00040.

HANAHAN, Douglas; WEINBERG, Robert A.. Hallmarks of Cancer: the next generation. Cell, [S.L.], v. 144, n. 5, p. 646-674, mar. 2011. Elsevier BV. http://dx.doi.org/10.1016/j.cell.2011.02.013.

GUERRA, Maximiliano Ribeiro et al. Risco de Câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Revista Brasileira de Cancerologia, [S. l.], v. 51, n. 3, p. 227-234, 2005.

CRISPEN, Paul L.; KUSMARTSEV, Sergei. Mechanisms of immune evasion in bladder cancer. Cancer Immunology, Immunotherapy, [S.L.], v. 69, n. 1, p. 3-14, 6 dez. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s00262-019-02443-4.

BUCHBINDER, Elizabeth I.; DESAI, Anupam. CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. American Journal Of Clinical Oncology, [S.L.], v. 39, n. 1, p. 98-106, fev. 2016. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/coc.0000000000000239.

SCHUMACHER, Ton N.; SCHREIBER, Robert D.. Neoantigens in cancer immunotherapy. Science, [S.L.], v. 348, n. 6230, p. 69-74, 2 abr. 2015. American Association for the Advancement of Science (AAAS). http://dx.doi.org/10.1126/science.aaa4971.

BURR, Marian L.; SPARBIER, Christina E.; CHAN, Kah Lok; CHAN, Yih-Chih; KERSBERGEN, Ariena; LAM, Enid Y.N.; AZIDIS-YATES, Elizabeth; VASSILIADIS, Dane; BELL, Charles C.; GILAN, Omer. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, [S.L.], v. 36, n. 4, p. 385-401, out. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.ccell.2019.08.008.

JAIN, Prantesh; JAIN, Chhavi; VELCHETI, Vamsidhar. Role of immune-checkpoint inhibitors in lung cancer. Therapeutic Advances In Respiratory Disease, [S.L.], v. 12, p. 1-13, jan. 2018. SAGE Publications. http://dx.doi.org/10.1177/1753465817750075.

WEI, Spencer C.; ANANG, Nana-Ama A. S.; SHARMA, Roshan; ANDREWS, Miles C.; REUBEN, Alexandre; LEVINE, Jacob H.; COGDILL, Alexandria P.; MANCUSO, James J.; WARGO, Jennifer A.; PE’ER, Dana. Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings Of The National Academy Of Sciences, [S.L.], v. 116, n. 45, p. 22699-22709, 21 out. 2019. Proceedings of the National Academy of Sciences. http://dx.doi.org/10.1073/pnas.1821218116.

WEI, Spencer C.; DUFFY, Colm R.; ALLISON, James P.. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, [S.L.], v. 8, n. 9, p. 1069-1086, 16 ago. 2018. American Association for Cancer Research (AACR). http://dx.doi.org/10.1158/2159-8290.cd-18-0367.

GIBNEY, Geoffrey T; WEINER, Louis M; ATKINS, Michael B. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. The Lancet Oncology, [S.L.], v. 17, n. 12, p. 542-551, dez. 2016. Elsevier BV.http://dx.doi.org/10.1016/s1470-2045(16)30406-5

WEI, Spencer C.; LEVINE, Jacob H.; COGDILL, Alexandria P.; ZHAO, Yang; ANANG, Nana-Ama A.s.; ANDREWS, Miles C.; SHARMA, Padmanee; WANG, Jing; WARGO, Jennifer A.; PE’ER, Dana. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell, [S.L.], v. 170, n. 6, p. 1120-1133, set. 2017. Elsevier BV. http://dx.doi.org/10.1016/j.cell.2017.07.024.

GIDE, Tuba N.; QUEK, Camelia; MENZIES, Alexander M.; TASKER, Annie T.; SHANG, Ping; HOLST, Jeff; MADORE, Jason; LIM, Su Yin; VELICKOVIC, Rebecca; WONGCHENKO, Matthew. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, [S.L.], v. 35, n. 2, p. 238-255, fev. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.ccell.2019.01.003.

BYUN, David J.; WOLCHOK, Jedd D.; ROSENBERG, Lynne M.; GIROTRA, Monica. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology, [S.L.], v. 13, n. 4, p. 195-207, 20 jan. 2017. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nrendo.2016.205.

DAS, Rituparna; VERMA, Rakesh; SZNOL, Mario; BODDUPALLI, Chandra Sekhar; GETTINGER, Scott N.; KLUGER, Harriet; CALLAHAN, Margaret; WOLCHOK, Jedd D.; HALABAN, Ruth; DHODAPKAR, Madhav V.. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo. The Journal Of Immunology, [S.L.], v. 194, n. 3, p. 950-959, 24 dez. 2014. The American Association of Immunologists. http://dx.doi.org/10.4049/jimmunol.1401686.

CURRAN, M. A.; MONTALVO, W.; YAGITA, H.; ALLISON, J. P.. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proceedings Of The National Academy Of Sciences, [S.L.], v. 107, n. 9, p. 4275-4280, 16 fev. 2010. Proceedings of the National Academy of Sciences. http://dx.doi.org/10.1073/pnas.0915174107.

ROTTE, Anand. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal Of Experimental & Clinical Cancer Research, [S.L.], v. 38, n. 1, p. 1-12, 13 jun. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s13046-019-1259-z.

MELO, Karina Mescouto; CARVALHO, Beatriz Tavares Costa. Células T regulatórias: mecanismos de ação e função nas doenças humanas. Rev bras alerg imunopatol, v. 32, n. 5, p. 184-8, 2009.

SCHNEIDER, Helga; RUDD, Christopher E.. Tyrosine Phosphatase SHP-2 Binding to CTLA-4: absence of direct yvkm/yfip motif recognition. Biochemical And Biophysical Research Communications, [S.L.], v. 269, n. 1, p. 279-283, mar. 2000. Elsevier BV. http://dx.doi.org/10.1006/bbrc.2000.2234.

MOCELLIN, Simone; NITTI, Donato. CTLA-4 blockade and the renaissance of cancer immunotherapy. Biochimica Et Biophysica Acta (Bba) - Reviews On Cancer, [S.L.], v. 1836, n. 2, p. 187-196, dez. 2013. Elsevier BV. http://dx.doi.org/10.1016/j.bbcan.2013.05.003.

FATHMAN, C. Garrison; LINEBERRY, Neil B.. Molecular mechanisms of CD4+ T-cell anergy. Nature Reviews Immunology, [S.L.], v. 7, n. 8, p. 599-609, 6 jul. 2007. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nri2131.

SALMANINEJAD, Arash; VALILOU, Saeed Farajzadeh; SHABGAH, Arezoo Gowhari; ASLANI, Saeed; ALIMARDANI, Malihe; PASDAR, Alireza; SAHEBKAR, Amirhossein. PD‐1/PD‐L1 pathway: basic biology and role in cancer immunotherapy. Journal Of Cellular Physiology, [S.L.], v. 234, n. 10, p. 16824-16837, 19 fev. 2019. Wiley. http://dx.doi.org/10.1002/jcp.28358.

SHARPE, Arlene H.; PAUKEN, Kristen E.. The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, [S.L.], v. 18, n. 3, p. 153-167, 13 nov. 2017. Springer Science and Business Media LLC. http://dx.doi.org/10.1038/nri.2017.108.

ABRIL-RODRIGUEZ, Gabriel; RIBAS, Antoni. SnapShot: immune checkpoint inhibitors. Cancer Cell, [S.L.], v. 31, n. 6, p. 848-848.e1, jun. 2017. Elsevier BV. http://dx.doi.org/10.1016/j.ccell.2017.05.010.

LARKIN, James; CHIARION-SILENI, Vanna; GONZALEZ, Rene; GROB, Jean Jacques; COWEY, C. Lance; LAO, Christopher D.; SCHADENDORF, Dirk; DUMMER, Reinhard; SMYLIE, Michael; RUTKOWSKI, Piotr. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal Of Medicine, [S.L.], v. 373, n. 1, p. 23-34, 2 jul. 2015. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1504030.

Downloads

Publicado

09/07/2024

Edição

Seção

Artigos

Como Citar

SOUZA , Maria Fernanda Figueiredo de et al. Monoterapia ou terapia combinada com inibidores de checkpoint imunológico: comparando efeitos aditivos e mecanismos diferenciais na resposta antitumoral. Journal of Social Issues and Health Sciences (JSIHS), [S. l.], v. 1, n. 6, 2024. DOI: 10.5281/zenodo.13729930. Disponível em: https://ojs.thesiseditora.com.br/index.php/jsihs/article/view/173.. Acesso em: 9 out. 2024.